Implantable device for long-term delivery of drugs
A device for sustained delivery of a poorly water soluble drug is described. A drug reservoir within the device, when in operation, contains an aqueous suspension of the drug mixed with a suspension of an excipient that, in one embodiment, generates acidic groups for a sustained period of time to maintain a desired pH in the aqueous suspension that in turn provides a constant concentration of a soluble form of the drug.
1. A drug delivery device, comprising:
a non-erodible, non-porous housing member defining a reservoir, said housing member having a water impermeable outer surface and first and second opposing ends;
a porous partition positioned in the first end of the housing member;
contained within said reservoir, a drug formulation comprised of a sparingly water soluble drug and a solubility-modifying excipient, said sparingly water soluble drug having a soluble form and an insoluble form, wherein the insoluble form of the drug is retained in the reservoir, and wherein said solubility-modifying excipient is capable of generating acid groups to provide a concentration of the drug, in an aqueous suspension when the drug formulation is hydrated, to provide release of a therapeutic dose of the drug from the device over a period of between about 2-12 months, as the soluble form of the drug freely diffuses out of the device across said partition; and
wherein release of the therapeutic dose is dependent on pH of the drug formulation and independent of pore size of the porous partition.
2. The device according to claim 1 , wherein said drug is a neuroleptic agent.
3. The device according to claim 2 , wherein the drug is present in soluble and insoluble forms in a total amount of greater than 100 mg/mL.
4. The device according to claim 3 , wherein the soluble fraction of drug is less than 1% of the total.
5. The device according to claim 2 , wherein the neuroleptic agent is risperidone, 9-hydroxyrisperidone or a pharmaceutically acceptable salt thereof.
6. The device according to claim 2 , wherein the neuroleptic agent is olanzapine, paliperidone, asenapine, haloperidol or aripiprazole or a pharmaceutically acceptable salt thereof.
7. The device according to claim 2 , wherein the total amount of said neuroleptic agent loaded in said reservoir is greater than 100 mg.
8. The device according to claim 1 , wherein the solubility-modifying excipient is a biocompatible, bioerodible polymer.
9. The device according to claim 8 , wherein the polymer is selected from the group of polylactides, polyglycolides, and copolymers thereof.
10. The device according to claim 9 , wherein the polymer is a co-polymer of polylactic acid and polyglycolic acid monomeric units, wherein the polylactic acid content is between about 50% to 100%.
11. The device of claim 1 , wherein the solubility-modifying excipient is an erodible polymer or a degradable polymer.
12. The device of claim 11 , wherein the polymer is polymerized from a monomer selected from the group consisting of lactic acid, glycolic acid, and lactide, glyclode.
13. The device of claim 11 , wherein the polymer is a poly(lactic-co-glycolid acid) copolymer.
14. The device of claim 1 , wherein the solubility-modifying excipient is water insoluble.
15. The device of claim 14 , wherein the solubility-modifying excipient in its insoluble form is retained by the porous partition.
16. The device of claim 1 , wherein the solubility-modifying excipient is a water insoluble polymer.
17. The device of claim 16 , wherein the solubility-modifying excipient undergoes hydrolysis to form a water-soluble monomer.
18. The device according to claim 1 , wherein the housing member is water impermeable.
19. The device according to claim 1 , wherein the housing member is a metal.
20. The device according to claim 1 , wherein the porous partition is selected from a porous polymer membrane, a sintered metallic membrane, and a ceramic membrane.
21. The device according to claim 1 , wherein the drug is buprenorphine.
22. A method for treating a patient suffering from a psychotic disorder, comprising:
implanting a device according to claim 1 , wherein the drug is a neuroleptic agent and is delivered at a substantially constant release rate for the period.
23. The method according to claim 22 , wherein the device is implanted subcutaneously.